Results 61 to 70 of about 3,406 (148)
Background Early reperfusion and first‐pass effect are key procedural end points in large‐vessel occlusion stroke thrombectomy. Because of greater fibrin specificity, tenecteplase may achieve higher early reperfusion rates compared with alteplase, yet ...
Tyler M. Bielinski +9 more
doaj +1 more source
Coronary artery disease is one of the leading causes of death globally. Despite the increased number of percutaneous coronary intervention (PCI) capable facilities, fibrinolytic therapy is still being utilized especially in rural areas.
Adham Mohamed PharmD +19 more
doaj +1 more source
Tenecteplase in large-vessel occlusion with or without thrombectomy: a meta-analysis
BackgroundDespite the growing adoption of Tenecteplase for stroke thrombolysis, key questions such as the role of bridging therapy and extended-window use in large-vessel occlusion (LVO) patients with or without access to endovascular thrombectomy (EVT ...
Ahmed Alkhiri +9 more
doaj +1 more source
Background The aim of this study was to investigate the efficacy and safety of tenecteplase versus alteplase in patients with acute ischemic stroke, considering their diabetes history and admission hyperglycemia status.
Huihui Liu +7 more
doaj +1 more source
Evaluating the Safety of Tenecteplase Versus Alteplase for Acute Ischemic Stroke
Background/Objectives: This study aims to compare the safety of tenecteplase versus alteplase for acute ischemic stroke. Methods: This was a multicenter, retrospective cohort study including 11 Memorial Hermann Health System hospitals in Houston from 7 ...
Salma Guerrero Miranda +4 more
doaj +1 more source
BackgroundThe optimal reperfusion approach for acute ischemic stroke (AIS) due to large vessel occlusion (LVO) remains under debate. While endovascular thrombectomy (EVT) is the standard treatment, the role of intravenous thrombolysis before EVT ...
Wenkui Li +8 more
doaj +1 more source
Context This study will emphasise the importance of Tenecteplase being ideally suited as a first-choice drug for thrombolysis in AIS in developing countries, considering the numerous challenges which are faced in these parts of the world.
Neeraj Basantani +3 more
doaj +1 more source

